Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract Cancer
PurposeThe clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with gemcitabine plus cisplatin were investigated.Materials and MethodsA total of 52 BTC patients treated with palliative gemcitabine plus cisplatin wer...
Saved in:
Published in | Cancer research and treatment Vol. 53; no. 1; pp. 162 - 171 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Korea (South)
Korean Cancer Association
01.01.2021
대한암학회 |
Subjects | |
Online Access | Get full text |
ISSN | 1598-2998 2005-9256 2005-9256 |
DOI | 10.4143/crt.2020.704 |
Cover
Abstract | PurposeThe clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with gemcitabine plus cisplatin were investigated.Materials and MethodsA total of 52 BTC patients treated with palliative gemcitabine plus cisplatin were included. Multiplexed immunohistochemistry was performed on tumor tissues, and immune infiltrates were separately analyzed for the stroma, tumor margin, and tumor core.ResultsThe density of CD8+ T cells, FoxP3- CD4+ helper T cells, and FoxP3+ CD4+ regulatory T cells was significantly higher in the tumor margin than in the stroma and tumor core. The density of LAG3- or TIM3-expressing CD8+ T cell and FoxP3- CD4+ helper T cell infiltrates was also higher in the tumor margin. In extrahepatic cholangiocarcinoma, there was a higher density of T cell subsets in the tumor core and regulatory T cells in all regions. A high density of FoxP3- CD4+ helper T cells in the tumor margin showed a trend toward better progression-free survival (PFS) (p=0.092) and significantly better overall survival (OS) (p=0.012). In multivariate analyses, a high density of FoxP3- CD4+ helper T cells in the tumor margin was independently associated with favorable PFS and OS. ConclusionThe tumor margin is the major site for the active infiltration of T cell subsets with higher levels of LAG3 and TIM3 expression in BTC. The density of tumor margin-infiltrating FoxP3- CD4+ helper T cells may be associated with clinical outcomes in BTC patients treated with gemcitabine plus cisplatin. |
---|---|
AbstractList | The clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with gemcitabine plus cisplatin were investigated.PURPOSEThe clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with gemcitabine plus cisplatin were investigated.A total of 52 BTC patients treated with palliative gemcitabine plus cisplatin were included. Multiplexed immunohistochemistry was performed on tumor tissues, and immune infiltrates were separately analyzed for the stroma, tumor margin, and tumor core.MATERIALS AND METHODSA total of 52 BTC patients treated with palliative gemcitabine plus cisplatin were included. Multiplexed immunohistochemistry was performed on tumor tissues, and immune infiltrates were separately analyzed for the stroma, tumor margin, and tumor core.The density of CD8+ T cells, FoxP3- CD4+ helper T cells, and FoxP3+ CD4+ regulatory T cells was significantly higher in the tumor margin than in the stroma and tumor core. The density of LAG3- or TIM3-expressing CD8+ T cell and FoxP3- CD4+ helper T cell infiltrates was also higher in the tumor margin. In extrahepatic cholangiocarcinoma, there was a higher density of T cell subsets in the tumor core and regulatory T cells in all regions. A high density of FoxP3- CD4+ helper T cells in the tumor margin showed a trend toward better progression-free survival (PFS) (p=0.092) and significantly better overall survival (OS) (p=0.012). In multivariate analyses, a high density of FoxP3- CD4+ helper T cells in the tumor margin was independently associated with favorable PFS and OS.RESULTSThe density of CD8+ T cells, FoxP3- CD4+ helper T cells, and FoxP3+ CD4+ regulatory T cells was significantly higher in the tumor margin than in the stroma and tumor core. The density of LAG3- or TIM3-expressing CD8+ T cell and FoxP3- CD4+ helper T cell infiltrates was also higher in the tumor margin. In extrahepatic cholangiocarcinoma, there was a higher density of T cell subsets in the tumor core and regulatory T cells in all regions. A high density of FoxP3- CD4+ helper T cells in the tumor margin showed a trend toward better progression-free survival (PFS) (p=0.092) and significantly better overall survival (OS) (p=0.012). In multivariate analyses, a high density of FoxP3- CD4+ helper T cells in the tumor margin was independently associated with favorable PFS and OS.The tumor margin is the major site for the active infiltration of T cell subsets with higher levels of LAG3 and TIM3 expression in BTC. The density of tumor margin-infiltrating FoxP3- CD4+ helper T cells may be associated with clinical outcomes in BTC patients treated with gemcitabine plus cisplatin.CONCLUSIONThe tumor margin is the major site for the active infiltration of T cell subsets with higher levels of LAG3 and TIM3 expression in BTC. The density of tumor margin-infiltrating FoxP3- CD4+ helper T cells may be associated with clinical outcomes in BTC patients treated with gemcitabine plus cisplatin. The clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with gemcitabine plus cisplatin were investigated. A total of 52 BTC patients treated with palliative gemcitabine plus cisplatin were included. Multiplexed immunohistochemistry was performed on tumor tissues, and immune infiltrates were separately analyzed for the stroma, tumor margin, and tumor core. The density of CD8+ T cells, FoxP3- CD4+ helper T cells, and FoxP3+ CD4+ regulatory T cells was significantly higher in the tumor margin than in the stroma and tumor core. The density of LAG3- or TIM3-expressing CD8+ T cell and FoxP3- CD4+ helper T cell infiltrates was also higher in the tumor margin. In extrahepatic cholangiocarcinoma, there was a higher density of T cell subsets in the tumor core and regulatory T cells in all regions. A high density of FoxP3- CD4+ helper T cells in the tumor margin showed a trend toward better progression-free survival (PFS) (p=0.092) and significantly better overall survival (OS) (p=0.012). In multivariate analyses, a high density of FoxP3- CD4+ helper T cells in the tumor margin was independently associated with favorable PFS and OS. The tumor margin is the major site for the active infiltration of T cell subsets with higher levels of LAG3 and TIM3 expression in BTC. The density of tumor margin-infiltrating FoxP3- CD4+ helper T cells may be associated with clinical outcomes in BTC patients treated with gemcitabine plus cisplatin. PurposeThe clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with gemcitabine plus cisplatin were investigated.Materials and MethodsA total of 52 BTC patients treated with palliative gemcitabine plus cisplatin were included. Multiplexed immunohistochemistry was performed on tumor tissues, and immune infiltrates were separately analyzed for the stroma, tumor margin, and tumor core.ResultsThe density of CD8+ T cells, FoxP3- CD4+ helper T cells, and FoxP3+ CD4+ regulatory T cells was significantly higher in the tumor margin than in the stroma and tumor core. The density of LAG3- or TIM3-expressing CD8+ T cell and FoxP3- CD4+ helper T cell infiltrates was also higher in the tumor margin. In extrahepatic cholangiocarcinoma, there was a higher density of T cell subsets in the tumor core and regulatory T cells in all regions. A high density of FoxP3- CD4+ helper T cells in the tumor margin showed a trend toward better progression-free survival (PFS) (p=0.092) and significantly better overall survival (OS) (p=0.012). In multivariate analyses, a high density of FoxP3- CD4+ helper T cells in the tumor margin was independently associated with favorable PFS and OS. ConclusionThe tumor margin is the major site for the active infiltration of T cell subsets with higher levels of LAG3 and TIM3 expression in BTC. The density of tumor margin-infiltrating FoxP3- CD4+ helper T cells may be associated with clinical outcomes in BTC patients treated with gemcitabine plus cisplatin. Purpose The clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with gemcitabine plus cisplatin were investigated. Materials and Methods A total of 52 BTC patients treated with palliative gemcitabine plus cisplatin were included. Multiplexed immunohistochemistry was performed on tumor tissues, and immune infiltrates were separately analyzed for the stroma, tumor margin, and tumor core. Results The density of CD8+ T cells, FoxP3– CD4+ helper T cells, and FoxP3+ CD4+ regulatory T cells was significantly higher in the tumor margin than in the stroma and tumor core. The density of LAG3– or TIM3-expressing CD8+ T cell and FoxP3– CD4+ helper T cell infiltrates was also higher in the tumor margin. In extrahepatic cholangiocarcinoma, there was a higher density of T cell subsets in the tumor core and regulatory T cells in all regions. A high density of FoxP3– CD4+ helper T cells in the tumor margin showed a trend toward better progression-free survival (PFS) (p=0.092) and significantly better overall survival (OS) (p=0.012). In multivariate analyses, a high density of FoxP3– CD4+ helper T cells in the tumor margin was independently associated with favorable PFS and OS. Conclusion The tumor margin is the major site for the active infiltration of T cell subsets with higher levels of LAG3 and TIM3 expression in BTC. The density of tumor margin-infiltrating FoxP3– CD4+ helper T cells may be associated with clinical outcomes in BTC patients treated with gemcitabine plus cisplatin. KCI Citation Count: 0 |
Author | Kim, Jwa Hoon Ryoo, Baek-Yeol Kim, Ki-Hun Kim, Hyung-Don Song, Ki Byung Kim, Danbee Lee, Sunmin Kim, Kyu-pyo Hwang, Dae Wook Jeong, Jae Ho Song, Gi‐Won Kim, Sang-Yeob Lee, Jae Hoon Jung, Dong‐Hwan Yoo, Changhoon Hong, Seung-Mo Ryu, Yeon-Mi Shin, Jaehoon |
Author_xml | – sequence: 1 givenname: Hyung-Don surname: Kim fullname: Kim, Hyung-Don – sequence: 2 givenname: Jwa Hoon surname: Kim fullname: Kim, Jwa Hoon – sequence: 3 givenname: Yeon-Mi surname: Ryu fullname: Ryu, Yeon-Mi – sequence: 4 givenname: Danbee surname: Kim fullname: Kim, Danbee – sequence: 5 givenname: Sunmin surname: Lee fullname: Lee, Sunmin – sequence: 6 givenname: Jaehoon surname: Shin fullname: Shin, Jaehoon – sequence: 7 givenname: Seung-Mo surname: Hong fullname: Hong, Seung-Mo – sequence: 8 givenname: Ki-Hun surname: Kim fullname: Kim, Ki-Hun – sequence: 9 givenname: Dong‐Hwan surname: Jung fullname: Jung, Dong‐Hwan – sequence: 10 givenname: Gi‐Won surname: Song fullname: Song, Gi‐Won – sequence: 11 givenname: Dae Wook surname: Hwang fullname: Hwang, Dae Wook – sequence: 12 givenname: Jae Hoon surname: Lee fullname: Lee, Jae Hoon – sequence: 13 givenname: Ki Byung surname: Song fullname: Song, Ki Byung – sequence: 14 givenname: Baek-Yeol surname: Ryoo fullname: Ryoo, Baek-Yeol – sequence: 15 givenname: Jae Ho surname: Jeong fullname: Jeong, Jae Ho – sequence: 16 givenname: Kyu-pyo surname: Kim fullname: Kim, Kyu-pyo – sequence: 17 givenname: Sang-Yeob surname: Kim fullname: Kim, Sang-Yeob – sequence: 18 givenname: Changhoon surname: Yoo fullname: Yoo, Changhoon |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32878426$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002676768$$DAccess content in National Research Foundation of Korea (NRF) |
BookMark | eNptkU1v1DAQhi1URLeFG2fkI6hk8Uccx5dKJaWwUiUqCGfLsZ3FNGsvtoPKv8e7WypAnEaaeeadj_cEHPngLQDPMVrWuKZvdMxLgghaclQ_AguCEKsEYc0RWGAm2ooI0R6Dk5S-IdTUlOMn4JiSlrc1aRYgft6q7NQEL13K0Q1zdsFD5Q28iWHtQ8pOw9VmOzmtdqUEwwj7eRNitfKjm3Isab-GV-Huhlawu6zPYA87O00JOg_fusmp-BP2UekMO-W1jU_B41FNyT67j6fgy9W7vvtQXX98v-ouritd4zZXTBFKmeEW1YKIsUGMD4pTS6mg2tSEYCOM5YYZ1mKDWszaYWCNHSkWnA-GnoJXB10fR3mrnQzK7eM6yNsoLz71KykaTkTTFvb8wG7nYWONtr4cNsltdJuy_r7z74p3X4vOD8lbTBCmReDlvUAM32ebsty4pMsblLdhTpLUVAheDtmhL_6c9TDktykFeH0AdAwpRTs-IBjJneeyeC53nsviecHJP7h2eW9W2dRN_2_6Bb9qr10 |
CitedBy_id | crossref_primary_10_37349_etat_2023_00199 crossref_primary_10_3390_ph17121606 crossref_primary_10_1016_j_esmoop_2024_103969 crossref_primary_10_1158_1078_0432_CCR_24_1265 crossref_primary_10_3389_fmed_2022_857140 crossref_primary_10_3389_fonc_2022_969569 crossref_primary_10_1038_s41598_022_05694_x crossref_primary_10_1186_s13045_021_01103_4 crossref_primary_10_2147_CMAR_S474348 crossref_primary_10_3389_fimmu_2024_1482291 crossref_primary_10_1186_s12943_024_02047_2 crossref_primary_10_1186_s13046_022_02340_2 crossref_primary_10_3390_nu16234134 crossref_primary_10_3892_ijo_2023_5585 crossref_primary_10_3389_fimmu_2025_1453344 crossref_primary_10_1016_j_biopha_2024_117080 |
Cites_doi | 10.1016/S1470-2045(20)30109-1 10.1186/s40425-019-0797-4 10.1053/j.gastro.2018.08.030 10.1002/ijc.33013 10.1002/hep.30881 10.1016/j.cell.2020.05.017 10.1038/s41571-019-0175-7 10.1016/S2468-1253(19)30086-X 10.1038/labinvest.2014.155 10.1136/jitc-2020-000564 10.1038/s41577-018-0044-0 10.1038/s41577-020-0306-5 10.1038/nature13954 10.1056/NEJMoa0908721 10.1016/j.ejca.2019.07.022 10.1038/bjc.2013.610 10.1016/j.immuni.2018.03.023 10.1007/s00280-017-3353-2 10.4143/crt.2019.493 10.1038/bjc.2017.401 10.1016/j.humpath.2004.03.016 10.7554/eLife.36967 10.1016/j.humpath.2015.05.016 10.1016/S1470-2045(20)30157-1 10.1038/s41598-019-42986-1 10.1155/2012/890178 10.3390/cancers11030283 10.1007/s00262-012-1307-4 10.1158/1078-0432.CCR-11-3185 10.1101/cshperspect.a026583 |
ContentType | Journal Article |
Copyright | Copyright © 2021 by the Korean Cancer Association 2021 |
Copyright_xml | – notice: Copyright © 2021 by the Korean Cancer Association 2021 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ACYCR |
DOI | 10.4143/crt.2020.704 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2005-9256 |
EndPage | 171 |
ExternalDocumentID | oai_kci_go_kr_ARTI_9672968 PMC7812013 32878426 10_4143_crt_2020_704 |
Genre | Journal Article |
GrantInformation_xml | – fundername: Asan Institute for Life Sciences, Asan Medical Center grantid: 2017IL0752 |
GroupedDBID | --- 29B 5-W 53G 8JR 9ZL AAYXX ABDBF ACUHS ACYCR ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION DIK E3Z EBD EF. F5P HYE OK1 RPM TR2 C1A CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c418t-5a2335d7e04929f6057ba73e3393cd4221d9de7d5d581d08158bb56ef31977bd3 |
ISSN | 1598-2998 2005-9256 |
IngestDate | Sun Mar 09 07:53:15 EDT 2025 Thu Aug 21 14:09:59 EDT 2025 Thu Jul 10 22:11:35 EDT 2025 Mon Jul 21 05:46:52 EDT 2025 Tue Jul 01 03:18:50 EDT 2025 Thu Apr 24 23:10:44 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | CD4+ helper T cells Biliary tract neoplasms Tumor margin Multiplexed immunohistochemistry |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c418t-5a2335d7e04929f6057ba73e3393cd4221d9de7d5d581d08158bb56ef31977bd3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Hyung-Don Kim and Jwa Hoon Kim contributed equally to this work. |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC7812013 |
PMID | 32878426 |
PQID | 2439979293 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_9672968 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7812013 proquest_miscellaneous_2439979293 pubmed_primary_32878426 crossref_primary_10_4143_crt_2020_704 crossref_citationtrail_10_4143_crt_2020_704 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-01-01 |
PublicationDateYYYYMMDD | 2021-01-01 |
PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Korea (South) |
PublicationPlace_xml | – name: Korea (South) |
PublicationTitle | Cancer research and treatment |
PublicationTitleAlternate | Cancer Res Treat |
PublicationYear | 2021 |
Publisher | Korean Cancer Association 대한암학회 |
Publisher_xml | – name: Korean Cancer Association – name: 대한암학회 |
References | ref13 ref12 ref15 ref14 ref30 ref11 ref10 ref2 ref1 ref17 ref16 ref19 ref18 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref28 ref27 ref29 ref8 ref7 ref9 ref4 ref3 ref6 ref5 |
References_xml | – ident: ref4 doi: 10.1016/S1470-2045(20)30109-1 – ident: ref14 doi: 10.1186/s40425-019-0797-4 – ident: ref23 doi: 10.1053/j.gastro.2018.08.030 – ident: ref7 doi: 10.1002/ijc.33013 – ident: ref24 doi: 10.1002/hep.30881 – ident: ref25 doi: 10.1016/j.cell.2020.05.017 – ident: ref11 doi: 10.1038/s41571-019-0175-7 – ident: ref6 doi: 10.1016/S2468-1253(19)30086-X – ident: ref18 doi: 10.1038/labinvest.2014.155 – ident: ref5 doi: 10.1136/jitc-2020-000564 – ident: ref10 doi: 10.1038/s41577-018-0044-0 – ident: ref9 doi: 10.1038/s41577-020-0306-5 – ident: ref15 doi: 10.1038/nature13954 – ident: ref1 doi: 10.1056/NEJMoa0908721 – ident: ref2 doi: 10.1016/j.ejca.2019.07.022 – ident: ref13 doi: 10.1038/bjc.2013.610 – ident: ref22 doi: 10.1016/j.immuni.2018.03.023 – ident: ref20 doi: 10.1007/s00280-017-3353-2 – ident: ref8 doi: 10.4143/crt.2019.493 – ident: ref12 doi: 10.1038/bjc.2017.401 – ident: ref26 doi: 10.1016/j.humpath.2004.03.016 – ident: ref19 doi: 10.7554/eLife.36967 – ident: ref21 doi: 10.1016/j.humpath.2015.05.016 – ident: ref3 doi: 10.1016/S1470-2045(20)30157-1 – ident: ref29 doi: 10.1038/s41598-019-42986-1 – ident: ref28 doi: 10.1155/2012/890178 – ident: ref30 doi: 10.3390/cancers11030283 – ident: ref27 doi: 10.1007/s00262-012-1307-4 – ident: ref16 doi: 10.1158/1078-0432.CCR-11-3185 – ident: ref17 doi: 10.1101/cshperspect.a026583 |
SSID | ssj0064371 |
Score | 2.3088803 |
Snippet | PurposeThe clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with... The clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with gemcitabine... Purpose The clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with... |
SourceID | nrf pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 162 |
SubjectTerms | Biliary Tract Neoplasms - genetics Biliary Tract Neoplasms - pathology CD4-Positive T-Lymphocytes - metabolism Female Forkhead Transcription Factors - metabolism Humans Lymphocytes, Tumor-Infiltrating - immunology Male Original Prognosis 의학일반 |
Title | Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract Cancer |
URI | https://www.ncbi.nlm.nih.gov/pubmed/32878426 https://www.proquest.com/docview/2439979293 https://pubmed.ncbi.nlm.nih.gov/PMC7812013 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002676768 |
Volume | 53 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Cancer Research and Treatment, 2021, 53(1), , pp.162-171 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db5swFLXSVqr6Mu172Ze8aX1CdME2GB6bZFUyqdM0UalvFmDToaZQ0WRT9-t3bQMhWStteyGRMVjknFzfg--9RuhDkPIsZXLkssxPQaAw5qahz1yfjzIZwjUyNwGyX4LZGft87p8PBj96UUurZXqU_bozr-R_UIU2wFVnyf4Dst1NoQG-A75wBITh-FcY6_2EC2O3brqNq9rwfx1Ap4uxzvsh4-AZxqurqnbnZV4sTMXc8sKBGegrdZ3JlB2SsRM7E7VYmDDZcbEodFRdrFOpnIkmSN33Zm2L0xQMsjlyXeT6enXfUG52C2bFnfZX_W2C9s_EmVXr5m-3KzMtqKp0T4utzsDRVKn-mwri9d5UKGPRTNnTiNhK4q35tbWCN2hmbalnzfS2jWfg4QEwWa0jYcnoiNvti3twX18ZvCmIwZCRrULbdupuTu2gPcK5Xt7fOx5PxyftHK5XMz2bJqGH-9gf7ADtt5dv-DI7ZZ3fJVO2o2177kv8ED1odAc-tiR6hAaqfIz2T5vIiieobriE-1zCAChecwn3uYSrHP_JJWy5hIFLDo6xYRIuStwwCRsmYcubp-js5FM8mbnNfhxuxrxw6foJodSXXIGqJFEOQpinCaeK0ohmkhHiyUgqLn3pgwoCX9MP09QPVA5mnvNU0mdot6xK9QJhj4ajSCW6GqVkUrGIslDRMIj8JAuDhA2R0_6yImuK1es9UxYCRKuGRAAkQkMiAJIhOux6X9siLff0ew8gicusELqquv68qMRlLUA7zkUUgNAMwiF612IowNTq9bOkVNXqRhCt3Tk8Oh2i5xbTbriWEkPEN9DuOugBN8-UxXdTzp2Djw1C7OW993yFDtZ_p9dod1mv1BtwhZfp24a3vwFecLRI |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Spatial+Distribution+and+Prognostic+Implications+of+Tumor-Infiltrating+FoxP3-+CD4%2B+T+Cells+in+Biliary+Tract+Cancer&rft.jtitle=Cancer+research+and+treatment&rft.au=Kim%2C+Hyung-Don&rft.au=Kim%2C+Jwa+Hoon&rft.au=Ryu%2C+Yeon-Mi&rft.au=Kim%2C+Danbee&rft.date=2021-01-01&rft.eissn=2005-9256&rft.volume=53&rft.issue=1&rft.spage=162&rft_id=info:doi/10.4143%2Fcrt.2020.704&rft_id=info%3Apmid%2F32878426&rft.externalDocID=32878426 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1598-2998&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1598-2998&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1598-2998&client=summon |